SuperworthBridgeBio Oncology Therapeutics shares outstanding BBOT
Diluted shares outstanding, averaged over each quarter, from 2024.
- Latest quarter, to Jun 30, 2026
- 80.1M
- On a year earlier
- +59.5%
- more shares
BridgeBio Oncology Therapeutics had 80.1M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 59.5% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 80M | +436846% |
| FY2024 | 18.3K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 80.1M | +59% | |
| Q1 FY26 | 80K | −80% | |
| Q4 FY25 | 80M | +436846% | |
| Q3 FY25 | 43.5M | +392100% | |
| Q2 FY25 | 50.2M | +165% | |
| Q1 FY25 | 406.7K | −96% | |
| Q4 FY24 | 18.3K | n/a | |
| Q3 FY24 | 11.1K | n/a | |
| Q2 FY24 | 18.9M | n/a | |
| Q1 FY24 | 9.9M | n/a |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on BridgeBio Oncology Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.